ArticleInternational journal of women's health2026
Neoadjuvant Paclitaxel-Carboplatin Followed by Concurrent Chemoradiotherapy versus Concurrent Chemoradiotherapy Alone in Locally Advanced Cervical Cancer.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Concurrent chemoradiotherapy (CCRT) remains the standard of care for locally advanced cervical cancer, yet recurrence and treatment-related toxicity continue to limit outcomes. Neoadjuvant chemotherapy using a Paclitaxel-Carboplatin regimen followed by CCRT (NACT-CCRT) been proposed to improve therapeutic response while minimizing systemic toxicity. This study aimed to compare the efficacy and safety of NACT-CCRT versus CCRT alone in patients with locally advanced (FIGO IIA-IIIC) and metastatic (stage IVA) cervical cancer. Patients and Methods: Prospective cohort study was conducted at Hasan Sadikin General Hospital, Bandung, between July 2024 and September 2025. Sixty-five eligible patients were enrolled using convenience sampling, comprising 32 in the NACT+CCRT group and 33 in the CCRT group. Treatment response was assessed according to RECIST 1.1 criteria, and tumour size reduction was measured using pelvic MRI before and after therapy. Statistical analysis included independent t-tests, Chi-square tests, and Repeated Measures ANOVA, with significance set at p<0.05. Results: Patients receiving NACT-CCRT achieved higher complete and overall response rates (100%) compared to those treated with CCRT alone. Tumour reduction exceeding 75% was observed in both groups, with the NACT+CCRT group show lower mortality rate. No significant increase in treatment-related toxicity was noted. Conclusion: The combination of Paclitaxel Carboplatin-based neoadjuvant chemotherapy followed by chemoradiation appears to be an effective and well-tolerated approach for selected patients with locally advanced cervical cancer, particularly those with good performance status and large tumours. Nevertheless, larger randomized controlled trials and biomarker-driven studies are needed to validate these findings and identify subgroups that may achieve the most durable clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.